TRACON Pharmaceuticals Announces Dosing of First Patient in Phase 1/2 Trial of YH001 in Combination with Envafolimab and Doxorubicin in Front Line Sarcoma

November 21, 2022

https://www.globenewswire.com/news-release/2022/11/21/2559816/10391/en/TRACON-Pharmaceuticals-Announces-Dosing-of-First-Patient-in-Phase-1-2-Trial-of-YH001-in-Combination-with-Envafolimab-and-Doxorubicin-in-Front-Line-Sarcoma.html

SAN DIEGO, Nov. 21, 2022 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals, Inc. (Nasdaq:TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced dosing of the first patient in a Phase 1/2 trial evaluating the Company’s CTLA-4 antibody, YH001, in combination with its PD-L1 antibody envafolimab and with doxorubicin in front line therapy in patients with sarcoma (NCT 05448820).

Read more at globenewswire.com

Related news for (TCON)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.